MIGENIX to Initiate MX-3253 HCV Viral Kinetics Study in Treatment Naive Patients (Hep C Treatment)

MIGENIX to Initiate MX-3253 HCV Viral Kinetics Study in Treatment Naive Patients
T-Net British Columbia - Jan 24 9:54 AM
Vancouver, BC, January 24, 2006--(T-Net)--MIGENIX Inc. released the Company's plan to initiate a combination therapy viral kinetics clinical trial of celgosivir in Hepatitis C virus patients.Save to My Web

Anadys Pharmaceuticals to Present at the 24th Annual JP Morgan Healthcare Conference
[Press Release] PR Newswire via Yahoo! Finance - Jan 05 6:00 AM
Anadys Pharmaceuticals, Inc. announced today that it will present at the 24th Annual JP Morgan Healthcare Conference on Thursday, January 12, 2006 at 9:00 a.m. PST at the Westin St.Save to My Web

Limitation of combination therapy of Interferon and Ribavirin for older patients with chronic hepatitis C
News-Medical-Net - Jan 05 2:18 PM
A new Japanese study examining the effects of combination therapy on older patients with hepatitis C found more adverse effects necessitating discontinuation of treatment, lowering of dosages, and lower long-term benefits in this age group.Save to My Web

Anadys Pharmaceuticals to Present at the 24th Annual JP Morgan Healthcare Conference
FinanzNachrichten - Jan 05 6:25 AM
Listeners are encouraged to visit the website approximately five minutes prior to Anadys' presentation to download or install any necessary software.Save to My Web

MIGENIX Announces Board Changes http://www.migenix.com
T-Net British Columbia - Jan 10 7:10 AM
Vancouver, BC, January 10, 2006--(T-Net)--MIGENIX Inc. announced that Michael Abrams, Ph.D., has retired from its Board. This change reduces the size of the Board to eight directors from nine.Save to My Web

GlobeImmune raises $38M
bizjournals.com via Yahoo! Finance - Jan 10 2:06 PM
Biotech company GlobeImmune has raised $38 million through a round of Series B financing, the company said Tuesday.Save to My Web